Fig 1: Reduction of H3K4me3 via down-regulation of hSETD1A decreases ERBB2 and CCND1 expression and increases chemosensitivity. A, Western blots showing hSETD1A, ERBB2, CCND1 and H3K4me3 in pediatric primary cultured cell lines. B and C, Real-time PCR (B) and western blots (C) show increased ERBB2 and CCND1 expression and H3K4me3 levels in pediatric primary cultured cells following treatment with pET28-SETD1A-MHL (pET-SETD1A), compared to pET28-MHL (pET28) control. D, Chromatin immunoprecipitation with H3K4me3 IgG antibodies coupled with real-time PCR (ChIP-PCR) using CCND1 and ERBB2 promoter primers in pediatric primary cultured EPN cells following treatment with pET-SETD1A, compared to pET28. E, MTS assays showing cell viability in response to CPL or VCR following treatment with pET-SETD1A or pET28 in pediatric primary EPN cells. F and G, Real-time PCR (F) and western blots (G) show decreased ERBB2 and CCND1 expression and H3K4me3 levels in pediatric primary cultured cells following treatment with siSETD1A (pET-SETD1A), compared to control siRNA (siCtrl). D, Chromatin immunoprecipitation with H3K4me3 IgG antibodies coupled with real-time PCR (ChIP-PCR) using CCND1 and ERBB2 promoter primers in pediatric primary cultured EPN cells following treatment with siSETD1A and siCtrl. I, MTS assays showing cell viability in response to CPL or VCR following treatment with siCtrl or siSETD1A in pediatric primary EPN cells. Error bars show the standard deviation of three independent experiments. * P < .05.